Consequences of prenatal substance use Jump to ContentJump to Main Navigation
Show Summary Details

International Journal of Adolescent Medicine and Health

Editor-in-Chief: Merrick, Joav

Editorial Board Member: Birch, Diana ML / Blum, Robert W. / Greydanus, MD, Dr. HC (Athens), Donald E. / Hardoff, Daniel / Kerr, Mike / Levy, Howard B / Morad, Mohammed / Omar, Hatim A. / de Paul, Joaquin / Rydelius, Per-Anders / Shek, Daniel T.L. / Sher, Leo / Silber, Tomas J. / Towns, Susan / Urkin, Jacob / Verhofstadt-Deneve, Leni / Zeltzer, Lonnie / Tenenbaum, Ariel


SCImago Journal Rank (SJR) 2015: 0.346
Source Normalized Impact per Paper (SNIP) 2015: 0.310
Impact per Publication (IPP) 2015: 0.660

99,00 € / $149.00 / £75.00*

Online
ISSN
2191-0278
See all formats and pricing

 


Select Volume and Issue
Loading journal volume and issue information...

Consequences of prenatal substance use

Thitinart Sithisarn1 / Don T. Granger1 / 1

1Department of Pediatrics, University of Kentucky College of Medicine, Lexington, KY, USA

Corresponding author: Professor Henrietta S. Bada, MD, MPH, Department of Pediatrics, University of Kentucky, College of Medicine, Lexington, KY 40536, USA Phone: +1-859-323-5530, Fax: +1-859-257-6106

Citation Information: . Volume 24, Issue 2, Pages 105–112, ISSN (Online) 2191-0278, ISSN (Print) 0334-0139, DOI: 10.1515/ijamh.2012.016, November 2011

Publication History

Received:
2011-02-02
Revised:
2011-03-17
Accepted:
2011-03-20
Published Online:
2011-11-29

Abstract

Background: Prenatal substance use is a major public health problem and a social morbidity, with consequences on the drug user and the offspring.

Objective: This review focuses on the child and adolescent outcomes following in utero drug exposure.

Methods: Studies on the effects of specific substances, legal and illegal; i.e., tobacco or nicotine, alcohol, marijuana, cocaine, opiates, and methamphetamine were evaluated and analyzed.

Results: In general, manifestations of prenatal exposure to legal and illegal substances include varying deficits in birth anthropometric measurements, mild-to-moderate transient neurobehavioral alterations in infancy and long-term behavioral problems noted from early childhood to adolescence. Severity of expression of behavioral problems is influenced by environmental factors. Further, behavioral alterations following in utero drug exposure often exist with mental health co-morbidities.

Conclusion: Because of the long-term consequences of prenatal drug exposure on child and adolescent mental health, health providers need to promote substance use prevention, screen for exposure effects and provide or refer affected youths for intervention services. Preventive measures and treatment should consider other factors that may further increase the risk of psychopathology in the exposed children.

Keywords: alcohol; cocaine; marijuana; methamphetamine; opiate; prenatal substance exposure; tobacco

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Gunild Frey, Michael Schuster, Christoph Oberlinner, Annette Queier-Wahrendorf, Stefan Lang, and Mei Yong
Journal of Occupational and Environmental Medicine, 2015, Volume 57, Number 9, Page 965
[2]
Kathryn Polak, Nancy A. Haug, Haroldo E. Drachenberg, and Dace S. Svikis
Current Treatment Options in Psychiatry, 2015
[3]
A. M. Vaiserman
Current Diabetes Reports, 2015, Volume 15, Number 8
[4]
Ana Concheiro-Guisan and Marta Concheiro
Bioanalysis, 2014, Volume 6, Number 23, Page 3133
[6]
Sandra Cecconi, Gianna Rossi, Annalisa Castellucci, Gabriele D’Andrea, and Mauro Maccarrone
European Journal of Obstetrics & Gynecology and Reproductive Biology, 2014, Volume 178, Page 6
[7]
Katia Buch Haervig, Laust Hvas Mortensen, Anne Vinkel Hansen, and Katrine Strandberg-Larsen
Pharmacoepidemiology and Drug Safety, 2014, Volume 23, Number 5, Page 526
[8]
Melissa H. Watt, Christina S. Meade, Stephen Kimani, Jessica C. MacFarlane, Karmel W. Choi, Donald Skinner, Desiree Pieterse, Seth C. Kalichman, and Kathleen J. Sikkema
International Journal of Drug Policy, 2014, Volume 25, Number 2, Page 219
[9]
Marta Concheiro, Eva González-Colmenero, Elena Lendoiro, Ana Concheiro-Guisán, Ana de Castro, Angelines Cruz-Landeira, and Manuel López-Rivadulla
Therapeutic Drug Monitoring, 2013, Volume 35, Number 4, Page 502
[10]
F.M. Vassoler, E.M. Byrnes, and R.C. Pierce
Neuropharmacology, 2014, Volume 76, Page 269
[11]
John D. Elsworth, D. Eugene Redmond, and Robert H. Roth
Synapse, 2013, Volume 67, Number 9, Page 580

Comments (0)

Please log in or register to comment.